IBDEI1EY ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,25342,0)
 ;;=V12.03^^145^1538^39
 ;;^UTILITY(U,$J,358.3,25342,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25342,1,4,0)
 ;;=4^V12.03
 ;;^UTILITY(U,$J,358.3,25342,1,5,0)
 ;;=5^Hx of Malaria
 ;;^UTILITY(U,$J,358.3,25342,2)
 ;;=Hx of Malaria^303395
 ;;^UTILITY(U,$J,358.3,25343,0)
 ;;=V10.82^^145^1538^40
 ;;^UTILITY(U,$J,358.3,25343,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25343,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,25343,1,5,0)
 ;;=5^Hx of Malignant Melanoma
 ;;^UTILITY(U,$J,358.3,25343,2)
 ;;=Hx of Malignant Melanoma^295240
 ;;^UTILITY(U,$J,358.3,25344,0)
 ;;=V10.62^^145^1538^43
 ;;^UTILITY(U,$J,358.3,25344,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25344,1,4,0)
 ;;=4^V10.62
 ;;^UTILITY(U,$J,358.3,25344,1,5,0)
 ;;=5^Hx of Myeloid Leukemia
 ;;^UTILITY(U,$J,358.3,25344,2)
 ;;=Hx of Myeloid Leukemia^295233
 ;;^UTILITY(U,$J,358.3,25345,0)
 ;;=V10.63^^145^1538^41
 ;;^UTILITY(U,$J,358.3,25345,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25345,1,4,0)
 ;;=4^V10.63
 ;;^UTILITY(U,$J,358.3,25345,1,5,0)
 ;;=5^Hx of Monocytic Leukemia
 ;;^UTILITY(U,$J,358.3,25345,2)
 ;;=Hx of Monocytic Leukemia^295234
 ;;^UTILITY(U,$J,358.3,25346,0)
 ;;=V11.2^^145^1538^32
 ;;^UTILITY(U,$J,358.3,25346,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25346,1,4,0)
 ;;=4^V11.2
 ;;^UTILITY(U,$J,358.3,25346,1,5,0)
 ;;=5^Hx of Dysthymia
 ;;^UTILITY(U,$J,358.3,25346,2)
 ;;=Hx of Dysthymia^295251
 ;;^UTILITY(U,$J,358.3,25347,0)
 ;;=V15.81^^145^1538^60
 ;;^UTILITY(U,$J,358.3,25347,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25347,1,4,0)
 ;;=4^V15.81
 ;;^UTILITY(U,$J,358.3,25347,1,5,0)
 ;;=5^Noncompliance With Medical Treatment
 ;;^UTILITY(U,$J,358.3,25347,2)
 ;;=^295290
 ;;^UTILITY(U,$J,358.3,25348,0)
 ;;=V10.43^^145^1538^44
 ;;^UTILITY(U,$J,358.3,25348,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25348,1,4,0)
 ;;=4^V10.43
 ;;^UTILITY(U,$J,358.3,25348,1,5,0)
 ;;=5^Hx of Ovarian CA
 ;;^UTILITY(U,$J,358.3,25348,2)
 ;;=Hx of Ovarian CA^295221
 ;;^UTILITY(U,$J,358.3,25349,0)
 ;;=V12.71^^145^1538^45
 ;;^UTILITY(U,$J,358.3,25349,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25349,1,4,0)
 ;;=4^V12.71
 ;;^UTILITY(U,$J,358.3,25349,1,5,0)
 ;;=5^Hx of Peptic Ulcer Disease
 ;;^UTILITY(U,$J,358.3,25349,2)
 ;;=^303400
 ;;^UTILITY(U,$J,358.3,25350,0)
 ;;=V10.46^^145^1538^48
 ;;^UTILITY(U,$J,358.3,25350,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25350,1,4,0)
 ;;=4^V10.46
 ;;^UTILITY(U,$J,358.3,25350,1,5,0)
 ;;=5^Hx of Prostate Cancer
 ;;^UTILITY(U,$J,358.3,25350,2)
 ;;=Hx of Prostate Cancer^295224
 ;;^UTILITY(U,$J,358.3,25351,0)
 ;;=V11.0^^145^1538^50
 ;;^UTILITY(U,$J,358.3,25351,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25351,1,4,0)
 ;;=4^V11.0
 ;;^UTILITY(U,$J,358.3,25351,1,5,0)
 ;;=5^Hx of Schizophrenia
 ;;^UTILITY(U,$J,358.3,25351,2)
 ;;=Hx of Schizophrenia^295249
 ;;^UTILITY(U,$J,358.3,25352,0)
 ;;=V10.83^^145^1538^51
 ;;^UTILITY(U,$J,358.3,25352,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25352,1,4,0)
 ;;=4^V10.83
 ;;^UTILITY(U,$J,358.3,25352,1,5,0)
 ;;=5^Hx of Skin Cancer (Non-Melanoma)
 ;;^UTILITY(U,$J,358.3,25352,2)
 ;;=^295241
 ;;^UTILITY(U,$J,358.3,25353,0)
 ;;=V15.1^^145^1538^53
 ;;^UTILITY(U,$J,358.3,25353,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25353,1,4,0)
 ;;=4^V15.1
 ;;^UTILITY(U,$J,358.3,25353,1,5,0)
 ;;=5^Hx of Surgery To Heart And Great Vessels
 ;;^UTILITY(U,$J,358.3,25353,2)
 ;;=^295283
 ;;^UTILITY(U,$J,358.3,25354,0)
 ;;=V15.82^^145^1538^57
 ;;^UTILITY(U,$J,358.3,25354,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25354,1,4,0)
 ;;=4^V15.82
 ;;^UTILITY(U,$J,358.3,25354,1,5,0)
 ;;=5^Hx of Tobacco Use (not current)
